HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS		QUICK SEARCH:   [advanced] Author: Keyword(s): Year:  Vol:  Page:

This Article Full Text Full Text (PDF) Alert me when this article is cited Alert me if a correction is posted Services Email this article to a friend Similar articles in this journal Similar articles in PubMed Alert me to new issues of the journal Add to Personal Folders Download to citation manager Author home page(s): Craig Selzman Permission Requests Citing Articles Citing Articles via Google Scholar Google Scholar Articles by Selzman, C. Search for Related Content PubMed PubMed Citation Articles by Selzman, C. Related Collections Molecular biology

---

Original Articles: Adult Cardiac

Invited Commentary

Division of Cardiothoracic Surgery, University of Utah, 30 N 1900 E, 3C 127 SOM, Salt Lake City, UT 84132

(Email: craig.selzman@hsc.utah.edu).

The first 20% of the full text of this article appears below.

In the last 5 years, significant enthusiasm (both experimentally and clinically) exists to apply progenitor cells to modify the myocardial response to injury. In many ways, the popular appeal of stem cell therapy, as well as its vast potential, has led to the quick adoption of these approaches into human clinical trials. Meanwhile, much remains to be learned about individual cell types and their mechanism of action. In the article by Zeller and colleagues [1], the group from Indiana continues their investigation of the effects of mesenchymal stem cells (MSCs) to . . . [Full Text of this Article]